Quantitative analysis for Immix Biopharma, Inc. (IMMX) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Buy (57.0) (grade B). 28 signals analyzed (23 differentiated alt-data).
IMMX stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-28 | $9.66 | $8.58 | $8.60 |
| 2026-05-08 | $10.08 | $9.18 | $9.75 |
| 2026-05-20 | $9.05 | $8.47 | $8.94 |
| 2026-06-02 | $9.34 | $8.23 | $8.37 |
| 2026-06-12 | $8.64 | $8.04 | $8.45 |
| 2026-06-25 | $10.25 | $9.64 | $9.72 |
| 2026-07-08 | $12.00 | $10.71 | $11.00 |
| 2026-07-20 | $10.05 | $8.67 | $8.80 |
| 2026-07-30 | $8.63 | $8.26 | $8.55 |
| 2026-08-12 | $11.72 | $10.93 | $11.37 |
| 2026-08-24 | $13.80 | $12.90 | $13.61 |
| 2026-09-03 | $14.14 | $13.52 | $13.83 |
How Immix Biopharma, Inc. stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| ODTX | Odyssey Therapeutics, Inc. | $490M | — |
| CTNM | Contineum Therapeutics, Inc. Class A Common Stock | $501M | — |
| OCGN | Ocugen, Inc. | $460M | — |
| CBIO | Crescent Biopharma, Inc. | $521M | — |
View all Health Care stocks by valuation and signals →
Immix Biopharma, Inc. (IMMX) scores Buy (57.0), with no measured dimension below 42. Its highest are competitive moat at 87, analyst consensus at 82, across 3 measured dimensions. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| competitive moat | 87 |
| analyst consensus | 82 |
| technicals | 42 |
StoQuant analyzes 28 signals (23 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Immix Biopharma, Inc. (IMMX): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/IMMX"><img src="https://stoquant.com/badge/IMMX.svg" alt="Immix Biopharma, Inc. (IMMX) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.